Nervigen's roluperidone, a potential treatment for schizophrenia negative symptoms, is awaiting pivotal clinical data expected in 2027.
An integrated treatment model for schizophrenia and opioid use disorder demonstrated high medication adherence and significant reductions in hospitalizations and ED visits, highlighting the importance of coordinated pharmacotherapy for this dual-diagnosis population.
A small study of 19 patients with treatment-resistant depression found psilocybin was associated with significant symptom reduction, highlighting its potential as a novel therapeutic agent.
A new pharmacogenomic test is available to help explain non-response to ADHD medications, offering a clinical tool for optimizing stimulant prescribing.
A leading PTSD expert critiques the limited efficacy of SSRIs for PTSD and discusses the evolving landscape of treatments including MDMA, psilocybin, and virtual reality exposure therapy.
Clinical Pearls
Bite-sized clinical takeaways from today's literature (sources from Oct 02 – Jun 05)
- Consider lithium monotherapy as a robust first-line maintenance option for bipolar disorder given reinforcing evidence from case register studies.
- Utilize the new British Association for Psychopharmacology consensus guidelines to inform evidence-based pharmacological management of substance dependence.
- Implement integrated treatment models for patients with schizophrenia and opioid use disorder to improve medication adherence and reduce hospitalizations.
- Exercise caution with zonisamide due to rare but severe psychiatric adverse effects, including homicidal ideation, which necessitate immediate discontinuation.
- Review the 2025 Japanese Expert Consensus for symptom-specific antipsychotic recommendations, noting brexpiprazole, aripiprazole, and olanzapine as key first-line options for schizophrenia.
- Consider pharmacogenomic testing to explain non-response in ADHD patients when optimizing stimulant prescribing strategies.
- Monitor pediatric Tourette syndrome patients closely for high non-persistence with dopamine D2 receptor modulators and increased adverse event risks.
- Recognize the limited efficacy of SSRIs for PTSD and consider evolving treatments such as MDMA, psilocybin, or virtual reality exposure therapy in treatment-resistant cases.
- Evaluate flumazenil trials as a potential strategy to reverse benzodiazepine effects during electroconvulsive therapy and improve cognitive outcomes.
Drug Development 3
A 52-week open-label extension study of AST-001 in children with ASD demonstrates maintained efficacy and good tolerability among prior responders, providing preliminary long-term safety data for this investigational psychotropic.
The VA has launched a new clinical trial for MDMA, and recent data indicates psilocybin's antidepressant effects are both rapid and long-lasting, highlighting ongoing research into novel psychedelic treatments for psychiatric conditions.
Autobahn Therapeutics advances a thyroid hormone receptor agonist for bipolar depression into pivotal trials following positive Phase 2 results.
Diagnosis & Treatment 3
The 2025 Japanese Expert Consensus provides symptom-specific first-line antipsychotic recommendations for schizophrenia, highlighting brexpiprazole, aripiprazole, and olanzapine as key options for various clinical presentations and side-effect profiles.
A clinical trial investigating the use of flumazenil to reverse benzodiazepine effects during electroconvulsive therapy, addressing a common prescribing challenge in psychiatric treatment.
A clinical trial investigating the use of flumazenil to reverse benzodiazepine effects during electroconvulsive therapy to potentially improve cognitive outcomes in patients with depression or bipolar disorder.
Clinical Pearl 3
A real-world study of pediatric Tourette syndrome patients reveals high non-persistence with dopamine D2 receptor modulators and significantly increased odds of adverse events and healthcare utilization compared to non-treated peers.
This case report and literature review documents the first instance of homicidal ideation associated with zonisamide, highlighting a severe psychiatric adverse effect that necessitates medication discontinuation.
A randomized, double-blind, placebo-controlled trial evaluates the efficacy of cannabidiol for managing behavioral and psychological symptoms of vascular dementia.
Substance Use 1
Psilocybin shows potential to increase abstinence rates in patients with cocaine use disorder, highlighting a novel pharmacological approach to stimulant addiction treatment.
Mechanism of Action 1
This theoretical paper proposes a mechanistic model for psilocybin-induced neuroplasticity, addressing the paradox between 5-HT2A receptor activation and TrkB signaling, which informs the biological basis of psychedelic-assisted therapy.
Journal Article 2
A case register study reinforces lithium monotherapy as a first-line maintenance treatment for bipolar disorder, supporting its continued use for long-term pharmacological management.
A nationwide matched cohort study with co-twin comparison investigates the association between incident benzodiazepine and Z-drug use and the subsequent risk of developing alcohol- and drug-related problems.
Policy & Regulation 1
FDA issued a Complete Response Letter for Cingulate's CTx-1301, a timed-release dexmethylphenidate formulation for ADHD, citing manufacturing deficiencies rather than safety or efficacy concerns.